|Bid||348.75 x 1100|
|Ask||348.90 x 800|
|Day's range||325.17 - 349.41|
|52-week range||54.21 - 349.41|
|Beta (5Y monthly)||1.47|
|PE ratio (TTM)||233.80|
|Earnings date||05 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||184.92|
Dr. Shikha Jain, Assistant Professor of Medicine, University of Illinois Chicago, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
It's fair to say that Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) are dominating the coronavirus vaccine market these days. Their vaccines have fully immunized 86 million and 62 million Americans, respectively.
Shares of Moderna (NASDAQ: MRNA) jumped 7.8% to a record closing high of $348.83 on Friday after European health officials recommended authorizing the drugmaker's coronavirus vaccine for kids 12 and older. The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on Moderna's vaccine. The European Commission will now consider granting authorization for use in adolescents.